LG Chem has partnered with a global biotech firm to enhance its artificial intelligence (AI)-based drug development capabilities. The collaboration aims to shorten the discovery period for antibody drug candidates, thereby accelerating the development of cancer treatments.
On June 18, LG Chem announced that it has signed a joint research and licensing option agreement with UK-based Lab-Genius Therapeutics to discover multi-antibody cancer drug candidates. Under this agreement, LG Chem will provide an upfront payment and research funding, and will decide on further development and licensing options based on the evaluation criteria from the joint research results.
Lab-Genius is a biotech company that operates an AI-driven drug development platform called EVA™, which combines machine learning with high-throughput experimental techniques.
LG Chem explained that AI will design and produce multiple antibodies, and the results will be analyzed through machine learning. This iterative research cycle allows for rapid identification of optimal candidates by incorporating data from previous designs. Additionally, the analysis will provide more precise insights into the efficacy, toxicity, response patterns, and sensitivity of candidates across different patient groups.
The goal is to reduce the typical discovery period for antibody drug candidates, which usually exceeds five years, to about half that time and to expedite the entry into preclinical stages.
So Jin-eon, head of LG Chem's Life Sciences Research and Development Division, stated, "We will quickly identify drug candidates that have higher efficacy and lower toxicity than existing drug substances in the area of cancer treatment, where there is a high unmet medical need."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.